A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11145 participants.
Also called NCT01156571
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 11,145 participants
- Sponsor
- Registry
-
NCT01156571
-
- Other papers using this trial's data
- Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial
- Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
- Effect of platelet inhibition with cangrelor during PCI on ischemic events
- Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial
- Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
- Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention)
- Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
- Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
- The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
- Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01156571. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2013-06-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
- Acronym
- CHAMPION
- Condition
- Atherosclerosis
- Condition
- Percutaneous Coronary Intervention
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- cangrelor P2Y12 (platelet) inhibitor
- Intervention (Drug)
- Clopidogrel - 300 or 600 mg (study arm)
- Intervention (Drug)
- Clopidogrel 600 mg post cangrelor
- Lead sponsor
- The Medicines Company
Record details
- Record id
cardio:ct-nct01156571- Content hash
b557b285187692a2acb390efc06c29941c339afefe2f7435d4b36dab04b05976